Aerobic fitness and opioidergic inhibition of cardiovascular stress reactivity.
Aerobic fitness and opioidergic inhibition of cardiovascular stress reactivity.
复制标题
有氧健身和阿片类药物抑制心血管应激反应。
DOI：
10.1111/j.1469-8986.1992.tb02047.x
复制
发表时间：
1992
期刊：
影响因子：
3.7
通讯作者：
Wilson,JF
中科院分区：
文献类型：
--
作者：
McCubbin,JA;Cheung,R;Montgomery,TB;Bulbulian,R;Wilson,JF
内源性阿片类药物在有氧健身诱导的心血管应激反应性下降中的作用通过比较阿片类药物拮抗剂与纳洛酮对具有高与低有氧健身水平的年轻人对应激反应的影响来检查。对240名受试者进行了活动问卷调查，并招募了具有最高（Fit）和最低（Nonfit）有氧活动特征的男性进行最大耗氧量（Vo2max）跑步机测试和心理应激测试（最终样本N=28）。在用纳洛酮（Trexan，DuPont）或安慰剂预处理后，在计算机控制的算术任务中测量心率和血压。在安慰剂激发期间，与不健康受试者相比，健康受试者在应激期间的心率反应性较低，在应激前和应激恢复期间的平均动脉血压较低。纳洛酮通过增加心率反应性和提高Fit受试者的平均动脉血压来消除这些反应性差异。这些数据表明，有氧健身与循环应激反应的阿片类抑制增强。阿片类药物对应激反应的调节作用可能是降低心血管疾病健康相关风险的重要机制。
The role of endogenous opioids in aerobic fitness‐induced decrements in cardiovascular stress reactivity was examined by comparing the effects of opioid antagonism with naltrexone on responses to stress in young adults with high versus low levels of aerobic fitness. Two hundred forty subjects were given an activity questionnaire and males with the highest (Fit) and lowest (Nonfit) aerobic activity profiles were recruited for maximal oxygen consumption (Vo2max) treadmill testing and psychological stress testing (final sample N=28). Heart rate and blood pressures were measured during performance on a computer‐controlled arithmetic task after pretreatment with either naltrexone (Trexan, DuPont) or a placebo. During placebo challenges, Fit subjects, compared with Nonfit, showed lower heart rate reactivity during stress and lower mean arterial blood pressures immediately before and during recovery from stress. Naltrexone eliminated these reactivity differences by increasing heart rate reactivity and raising mean arterial blood pressure in Fit subjects. These data suggest that aerobic fitness is associated with enhanced opioidergic inhibition of circulatory stress reactivity. Opioidergic modulatory effects on stress reactivity may comprise an important mechanism in fitness‐associated risk reduction for cardiovascular disease.